ICU MEDICAL INC/DEICUI
ICU MEDICAL INC/DE Segments Disclosure
SEGMENT DATA
The Company has a single operating and reportable segment. The segment is organized by and derives revenues from the manufacture and sale of our medical products which are used in infusion therapy, vascular access, and vital care applications. Our product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, IV catheters, and sharps safety products; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. We also offer IV Solutions products through a commercial relationship with the joint venture. Our product lines, as disclosed in Note 4: Revenue, were determined to be a single operating segment as discrete financial information by product-line is limited to revenue and standard cost. Other cost of sale expenses, which include above-site manufacturing costs, manufacturing variances and supply chain costs including freight and warehousing are not allocated to individual product lines. Similarly, quality, regulatory and other operating expenses are only provided to our chief operating decision maker ("CODM") at the consolidated level.
The accounting policies of our single reportable segment are the same as those described in Note 1: Basis of Presentation and Significant Accounting Policies.
For information on disaggregation of revenues by product-line and geography, see Note 4: Revenue.
Our is our CODM. Our CODM uses net profit (loss) to manage our business activities on a consolidated basis and to evaluate and assess the performance of the Company when determining how to allocate capital resources. Our segment performance is monitored and resource allocation is determined during the annual budget/forecast processes. The measure of segment assets is reported on the consolidated balance sheets as total assets. In 2025, 2024 and 2023, expenditures for additions to long-lived assets were $97.0 million, $90.2 million, and $93.7 million, respectively.
The following table presents information about our segment revenue, segment profit or loss, and significant segment expenses (in thousands):
| Year ended December 31, | ||||||||||||||||||||
| 2025 | 2024 | 2023 | ||||||||||||||||||
| REVENUES | $ | 2,231,262 | $ | 2,382,046 | $ | 2,259,126 | ||||||||||||||
| Less: | ||||||||||||||||||||
Standard COGS(1) | 1,007,545 | 1,193,994 | 1,114,294 | |||||||||||||||||
Quality remediation/recall(2) | 40,459 | 19,126 | 58,243 | |||||||||||||||||
Other COGS(3) | 326,914 | 344,144 | 346,716 | |||||||||||||||||
Tariff expense(4) | 34,305 | — | — | |||||||||||||||||
| Selling, general and administrative | 625,210 | 638,762 | 606,693 | |||||||||||||||||
| Research and development | 87,495 | 88,615 | 85,344 | |||||||||||||||||
| Restructuring and integration | 66,505 | 59,840 | 41,258 | |||||||||||||||||
Other segment items(5) | (54,867) | (2,964) | (17,850) | |||||||||||||||||
| Interest expense | 93,338 | 106,541 | 102,727 | |||||||||||||||||
| Income tax provision (benefit) | 2,437 | 51,676 | (48,644) | |||||||||||||||||
| Equity in losses of unconsolidated affiliates | 1,189 | — | — | |||||||||||||||||
| Consolidated net income (loss) | $ | 732 | $ | (117,688) | $ | (29,655) | ||||||||||||||
_______________
(1) Represents the average annual budgeted cost of producing each good sold in the period.
(2) Represents significant labor and material costs to replace or repair a product outside the scope of standard warranty and compliance costs related to quality systems and manufacturing operations.
(3) Includes costs related to capitalized manufacturing variances to standard COGS, supply chain and logistics costs including freight, inventory management and reserves, hardware service, quality and regulatory, and operations and supply chain management costs.
(4) For the year ended 2025, total tariff expense includes $3.1 million in tariffs typically grouped within standard COGS and $31.2 million typically grouped within other COGS. Prior year comparative data for tariff-related expenses is not presented as these costs were historically integrated within broad general ledger accounts and are not practicable to discretely calculate without unreasonable effort.
(5) Includes changes in fair value of contingent earn-out, interest income, gain/loss on disposition of assets, gain/loss on foreign exchange, other miscellaneous income/expense and gain on sale of business.
For information on depreciation and amortization expense, see Note 1: Basis of Presentation and Significant Accounting Policies.
Significant Customers
We sell products worldwide, on credit terms on an unsecured basis, as an OEM supplier, to independent medical supply distributors and directly to end customers. The manufacturers and distributors, in turn, sell our products to healthcare providers. In 2025, 2024 and 2023, we had net sales to a single distributor of 18%, 18% and 16%, respectively of consolidated worldwide net sales.
Geographic Information
The table below presents our gross long-lived assets, consisting of property, plant and equipment, by country or region (in thousands):
| As of December 31, | ||||||||||||||
| 2025 | 2024 | |||||||||||||
| Costa Rica | $ | 168,678 | $ | 156,149 | ||||||||||
| Mexico | 127,389 | 111,043 | ||||||||||||
| Other LATAM | 71,054 | 55,451 | ||||||||||||
| Canada | 1,982 | 5,284 | ||||||||||||
| Italy | 35,468 | 29,124 | ||||||||||||
| Spain | 21,532 | 17,141 | ||||||||||||
| Czech Republic | 14,111 | 11,909 | ||||||||||||
| Other Europe | 11,485 | 11,445 | ||||||||||||
| APAC | 28,239 | 27,550 | ||||||||||||
| Total Foreign | $ | 479,938 | $ | 425,096 | ||||||||||
| United States | 617,792 | 610,547 | ||||||||||||
| Worldwide Total | $ | 1,097,730 | $ | 1,035,643 | ||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 19, 2026 | Showing above |
| 2024 | Feb 27, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.